A950160 Stock Overview
Kolon TissueGene, Inc. engages in developing cell therapies to target various orthopedic diseases and degenerative disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kolon TissueGene, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,160.00 |
| 52 Week High | ₩16,900.00 |
| 52 Week Low | ₩7,710.00 |
| Beta | 0 |
| 1 Month Change | 3.40% |
| 3 Month Change | 24.97% |
| 1 Year Change | 18.06% |
| 3 Year Change | n/a |
| 5 Year Change | 19.22% |
| Change since IPO | -71.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| A950160 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.5% | 1.4% | 1.4% |
| 1Y | 18.1% | 7.8% | 8.3% |
Return vs Industry: A950160 exceeded the KR Biotechs industry which returned 7.8% over the past year.
Return vs Market: A950160 exceeded the KR Market which returned 8.3% over the past year.
Price Volatility
| A950160 volatility | |
|---|---|
| A950160 Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A950160's share price has been volatile over the past 3 months.
Volatility Over Time: A950160's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Moon-jong Noh | www.tissuegene.com |
Kolon TissueGene, Inc. engages in developing cell therapies to target various orthopedic diseases and degenerative disorders. The company develops cell therapies for osteoarthritis, including knee and hip; musculoskeletal system disorder comprising spinal disk; and vet medicine for knee. It also has collaboration with Kolon Life Science, Inc. The company was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018.
Kolon TissueGene, Inc. Fundamentals Summary
| A950160 fundamental statistics | |
|---|---|
| Market cap | ₩903.19b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A950160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950160 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A950160 perform over the long term?
See historical performance and comparison